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Josephus P. J. van Gestel,1 Casper W. Bollen,1 Marc B. Bierings,2 Jaap Jan Boelens,2
Nico M. Wulffraat,2 Adrianus J. van Vught1There is ongoing discussion whether survival improved for children requiring mechanical ventilation after
hematopoietic stem cell transplantation (HSCT). We reviewed the outcomes of 150 children who received
an allogeneic HSCT between January 1999 and April 2007, in a pediatric university hospital in The Nether-
lands. Thirty-five of the 150 patients received mechanical ventilation on 38 occasions. None of the recorded
risk factors was significantly associated with the requirement of mechanical ventilation. Sixteen admissions
resulted in death in the intensive care unit (ICU), giving a case fatality rate of 42% (95% confidence interval
26%-58%). ICUmortality was associated with multiorgan failure on the second day of admission and with the
use of high frequency oscillatory ventilation. Patients had higher pediatric risk of mortality scores than in pre-
vious studies, reflecting higher acuity of illness on admission to the ICU. Six-month survival in patients dis-
charged from the ICU was 82%. Compared to previous studies, we found an improvement in ICU survival
and survival 6 months after ICU discharge in a recent cohort of ventilated children after allogeneic HSCT,
even though our patients were more severely ill. Our results are promising, but they need to be confirmed
in larger, preferably multicenter, studies.
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Despite all its progress over the years, pediatric he-
matopoietic stem cell transplantation (HSCT) remains
a high risk procedure, which necessitates transfer to
the intensive care unit (ICU) in up to 44% of patients
[1]. Mortality in ventilated children after HSCT his-
torically was reported to be very high. Whether out-
come improved over the years is still a matter of
debate: a clear decrease in mortality over time could
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6/j.bbmt.2008.09.020[2], mostly because current outcome data in ventilated
patients were lacking. Two studies from the United
States, published after the inclusion period of the
meta-regression analysis, revealed conflicting results:
survival had clearly improved over time in 1 study
[3], whereas it did not differ by year of study in the
other [4]. More outcome data in this population are,
therefore, needed.
Only few studies investigated which factors were
associated with an increased risk of ICU admission in
children after HSCT [5-8]. A considerable proportion
of patients in these studies underwent autologous
transplantations, which may have limited general ap-
plicability of results. Moreover, patients in previous
studies often did not require mechanical ventilation
during their ICU stay, whereas this specifically is the
most uniform ICU treatment, and it is associated
with the largest increase in risk of mortality [4].
The main goal of the present study was to assess
outcome in a recent cohort of children requiring me-
chanical ventilation after allogeneic HSCT. Second,
we wanted to identify predictors for mortality in this
cohort and predictors for the requirement of mechan-
ical ventilation.1385
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Setting
This study was performed at the Wilhelmina
Children’s Hospital, which is part of the University
Medical Center Utrecht (Utrecht, The Netherlands).
In this hospital, about 30 allogeneic HSCTs in chil-
dren are performed annually. The multidisciplinary
14-bed pediatric ICU has approximately 650 admis-
sions each year; about 80% of them receive invasive
mechanical ventilation. The generally applied ventila-
tion strategies aim to limit tidal volumes to\8 mL/kg
and to restrict peak inspiratory pressures to\30 cm
H2O, while applying high positive end expiratory
pressures. Patients are ventilated in a pressure control
or pressure support mode. Patients requiring peak in-
spiratory pressures above 30 cm H2O or patients with
an oxygenation index ([mean airway pressure  FiO2
 100]/PaO2) .20 proceed to high frequency oscilla-
tory ventilation (HFOV). Ventilation is delivered by
a Servo 300 or Servo-i (Maquet, Sweden) for conven-
tional mechanical ventilation and a Sensormedics
3100A or 3100B (Viasys Healthcare, Madison, WI)
for HFOV.Patients
All children younger than 19 years of age, who re-
ceived an allogeneic HSCT in our hospital between
January 1999 and April 2007, were identified from
the HSCT database. Patients admitted to the ICU af-
ter HSCT were identified from a prospectively main-
tained ICU database. They were included when they
had received invasive mechanical ventilation for more
than 24 hours. Prior to the start of the HSCT proce-
dure, all parents, and when appropriate, all patients,
gave written informed consent to analyze deidentified
clinical data for study purposes.Data Collection
Patient data were collected from medical charts
and from the HSCT database. Data that were ab-
stracted included demographic information, preexist-
ing diagnosis requiring HSCT, number and type of
transplantations, type of donor and source of stem
cells. For those patients admitted to the ICU for me-
chanical ventilation, the following additional informa-
tion was recorded: presence of neutropenia, grade of
graft-versus-host disease (GVHD), cytomegalovirus
status (CMV), time interval between HSCT and ad-
mission to the ICU, reason for intubation, duration
of intubation, use of HFOV, pediatric risk of mortality
(PRISM) score [9], highest oxygenation index during
the first day of admission, and severity of organ dys-
function during the first 3 days of admission to the
ICU.Definitions
Indications for HSCT were categorized in the
following groups: malignancy, inborn error of metab-
olism, immunodeficiency, bone marrow failure syn-
drome, and miscellaneous inborn error (including
thalassemia, Morbus Glanzmann). GVHD was diag-
nosed and graded according to Glucksberg et al.
[10]. CMV status at admission to the ICU was catego-
rized as negative, infection (including reactivation), or
carrier. Neutropenia was defined as a polymorphonu-
clear leukocyte count of\500 cells per cubic millime-
ter of blood. Reasons for admission to the ICU were
grouped in the following categories: respiratory fail-
ure, neurologic deterioration, sepsis, arrest, bleeding,
and postoperative [11]. Number and severity of organ
dysfunction was assessed following the criteria of Wil-
kinson et al. [12]. The PRISM score [9] was used to as-
sess severity of illness on admission to the ICU. It is
a validated scoring system, applied by pediatric ICUs
worldwide. It is based on deteriorations of a number
of physiologic variables measured during the first 24
hours of ICU admission. Human leukocyte antigen
(HLA) matching was based on high-resolution typing
for class I and class II antigens for bone marrow and
peripheral blood stem cell (PBSC) donors (10 anti-
gens: A, B, C, DR, andDQ). For cord blood donors in-
termediate resolution criteria were used (Loci A and B
serologically and DRB1 by high-resolution typing)
[13]. A DPB1 mismatch was not taken into account.
For the analyses, patients were simply divided into
a matched or mismatched group. Identical cord blood
grafts according to the intermediate resolution criteria
mentioned above were regarded as matched.
Primary endpoint of the study was outcome (sur-
vival or death) at discharge from the ICU; secondary
endpoint was outcome (survival or death) 6 months
after discharge from the ICU.
Statistical Analysis
Differences in categoric demographic and clinical
variables were analyzed using Fisher’s exact test. Con-
tinuously distributed data were evaluated using Stu-
dent’s t-tests. The association between potential risk
factors and ICUadmission or ICUmortality was quan-
tified using univariable logistic regression analysis.
This was followed by stepwise multiple logistic regres-
sion analysis to identify those factors independently as-
sociated with ICU admission or ICU mortality. A
value of P\ .05 was considered to indicate statistical
significance. Data were analyzed using SPSS version
12.0.2 (SPSS, Chicago, IL).RESULTS
A flow chart of HSCTs and ICU admissions is
given in Figure 1. During the inclusion period, 175
56 ICU admissions
in 51 patients
excluded: 18 admissions
in 16 patients
(no MV or MV < 24 hours)
included: 38 admissions
in 35 patients
15 discharged from ICU
3 died on ICU
22 discharged from ICU
16 died on ICU
175 HSCTs
in 150 patients
Figure 1. Flow chart of ICU admissions and outcomes of children after allogeneic hematopoietic stem cell transplantation. HSCT, hematopoietic stem
cell transplantation; ICU, intensive care unit; MV, mechanical ventilation.
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Pediatric Allogeneic HSCT RecipientsHSCTs were performed in 150 patients: a second
transplantation was done in 23 patients, and 1 patient
received 3 transplantations. Fifty-one patients were
admitted to the ICU on 56 occasions: 2 patients were
admitted twice, 1 patient was admitted to the ICU
on 5 occasions. Eighteen admissions (16 patients) did
not receive mechanical ventilation for more than 24
hours and they were excluded. Three of the excluded
patients died in the ICU: 1 patient was admitted be-
cause of a sepsis, which rapidly deteriorated. Despite
intubation and resuscitation he died within 1 hour af-
ter admission. In 2 patients it was decided (in agree-
ment with the patients’ and parents’ wishes) to give
maximum support, but refrain from mechanical venti-
lation. Both patients died within 3 days after ICU ad-
mission.
The remaining 35 patients (23% of all HSCT re-
cipients) were included in the study. Because 3 patients
required 2 episodes of mechanical ventilation, me-
chanical ventilation was given on 38 occasions. Read-
missions for mechanical ventilation occurred 2 days,
214 days, and 219 days after the first admission.
They were considered to be separate treatment epi-
sodes and were analyzed accordingly. None of the in-
cluded patients had received noninvasive ventilation
before intubation or during weaning. The reasons to
start mechanical ventilation were respiratory failure
(n 5 26), neurologic deterioration (n 5 6), sepsis
(n5 4), cardiac arrest (n5 1), and postoperative (n5 1).
Sixteen patients died in the ICU, resulting in a case
fatality rate of 42% (95% confidence interval (CI) 26%to 58%). The cause of death for patients in the ICU
was respiratory failure (n 5 6), multiple organ system
failure (n5 7), sepsis (n5 1), Epstein Barr encephalitis
(n 5 1), and posttransplantation lymphoproliferative
disorder (n5 1). All 3 patients who received 2 episodes
of mechanical ventilation died in the ICU. During
ICU treatment 2 patients received renal replacement
therapy; both died in the ICU. The observed ICU
mortality (42%) corresponded to PRISM-based
predicted mortality (37%). However, there was
a wide variation between annually observed and pre-
dicted ICU mortality (Figure 2).
Three patients who were discharged from the ICU
died shortly afterward: 1 patient after 10 days (refrac-
tory GVHD), 1 after 20 days (refractory GVHD, Ep-
stein Barr reactivation, and pulmonary aspergillosis),
and 1 patient died 34 days after ICU discharge (idio-
pathic pneumonia syndrome, multiple viral infec-
tions). Early mortality rate (ie, death on the ICU or
shortly after discharge from the ICU), therefore, was
50% (95% CI 34% to 66%). Eighteen patients who
were discharged from the ICU were still alive 6
months later. Altogether, therefore, 18 of 38 ICU
admissions (47%) could be discharged from the ICU
and lived at least 6 months afterward.Risk Factors for the Requirement of Mechanical
Ventilation
Characteristics of all HSCT recipients are summa-
rized in Table 1. In this table, a comparison is made
Figure 2. Predicted mortality rates (based on PRISM scores) and observed mortality rates in children requiring mechanical ventilation after allogeneic
hematopoietic stem cell transplantation. ObsMort, observed ICU mortality rate; PredMort, predicted ICU mortality rate based on PRISM score [9].
1388 Biol Blood Marrow Transplant 14:1385-1393, 2008J. P. J. van Gestel et al.between ventilated and nonventilated children. Data
are analyzed per patient. When data were analyzed
with each transplantation as a separate event (ie, n 5
175 instead of n5 150), comparable results were found
(data not shown).
In the univariable analysis, year of transplantation
and type of donor were associated with the risk of
requiring mechanical ventilation (see Table 1). In the
multiple regression analysis, both year of transplanta-
tion (odds ratio 1.15, 95% CI 0.94-1.39, P 5 .17)
and type of donor (odds ratio 0.56, 95% CI 0.24-
1.35, P 5 .20) lost significance.Table 1. Characteristics of Pediatric Allogeneic Hematopoietic Ste
All HSCT Recipients HSCT Recipients W
(n 5 150) (n
Gender (female) 39%
Median Age (years) 6.5
Diagnosis
Malignancy 54%
Immunodeficiency 17%
Bone marrow failure 13%
Inborn error of metabolism 10%
Miscellaneous inborn error 5%
Type of Transplant
Bone marrow 69%
Cord blood 17%
Peripheral blood stem cells 16%
Type of donor (related) 43%
HLA mismatch 33%
More than 1 Transplantation 15%
Year of Transplantation 1999-2007 199
HSCT indicates hematopoietic stem cell transplantation; MV, mechanical vent
Patients who did not receive mechanical ventilation after their transplantationRisk Factors for Mortality in Ventilated Patients
Clinical characteristics of ventilated patients who
survived to ICU discharge are summarized in Table
2. Clinical characteristics of ventilated patients who
died during their ICU admission are summarized in
Table 3.
Results from the statistical comparison between
survivors and nonsurvivors are given in Table 4. In
the univariate analysis, number of organs failing on
day 2 and HFOV were significantly related with ICU
mortality. Both organ failure on day 2 (odds ratio
3.45, 95% CI 1.12-10.63, P 5 .03) and HFOV (oddsm Cell Transplantation Recipients
ho Did Not Receive MV HSCT Recipients Requiring MV
5 115) (n 5 35) P -Value
37% 46% .43
6.6 4.7 .56
56% 49% .56
17% 20% .62
16% 6% .16
8% 17% .12
4% 9% .39
70% 63% .41
15% 23% .30
17% 14% 1.00
47% 29% .06
32% 31% .68
17% 6% .11
9-2007 1999-2007 .05
ilation; HLA, human leukocyte antigen.
are compared with ventilated patients.
Table 2. Clinical Characteristics of the 22 Ventilated Pediatric Hematopoietic StemCell Transplantation RecipientsWho Survived
to ICU Discharge
Primary Diagnosis
Indication
for MV Diagnosis Necessitating MV
Time
Between ICU
and HSCT
(days)
Duration
of MV
(days)
Survival
after ICU
discharge
Grade
of
aGvHD
Neutropenia
admission
to ICU
Viral infection
on admission
to ICU
1 GM1-gangliosidosis resp. failure idiopathic pneumonia
syndrome
7 9 > 6 months 1 yes no
2 AML resp. failure engraftment syndrome,
hepatic VOD
10 12 > 6 months 1 no no
3 MPS I resp. failure diffuse alveolar hemorrhage 11 19 > 6 months 0 yes adenovirus
reactivation
4 beta thalassemia
major
resp. failure hepatic VOD with
pulmonary edema
14 8 > 6 months 0 yes no
5 MDS resp. failure idiopathic pneumonia
syndrome, hepatic VOD
24 20 > 6 months 0 no no
6 MDS resp. failure hepatic VOD with
pulmonary edema, acute
GVHD
25 15 10 days 4 no no
7 AML resp. failure intoxication cyclosporine
with pleural effusions
and multi-organ failure
29 2 > 6 months 0 no CMV
reactivation
8 Niemann-Pick
disease
resp. failure idiopathic pneumonia
syndrome, pulmonary
VOD
66 31 > 6 months 3 no no
9 alpha-mannosidose resp. failure idiopathic pneumonia
syndrome
82 17 34 days 1 no adenovirus
reactivation
10 MDS resp. failure interstitial pneumonitis,
only rhinovirus isolated
90 9 > 6 months 1 no rhinovirus
isolated
11 MPS VI resp. failure bronchiolitis obliterans,
no microorganism
identified
94 11 > 6 months 1 no no
12 CID resp. failure idiopathic pneumonia
syndrome, subglottic
stenosis
117 8 > 6 months NA no no
13 SAA resp. failure lobar pneumonia,
no microorganism
identified
171 21 > 6 months NA no no
14 T-cell ALL neur. det. Guillain-Barre syndrome 68 50 > 6 months 0 no no
15 cartilage hair
hypoplasia
neur. det. Acinetobacter sepsis
with encephalopathy
71 5 144 days 0 yes systemic
adenoviral
infection
16 relapsed AML neur. det. central nervous
system toxoplasmosis
171 37 > 6 months NA no no
17 AML neur. det. CNS, pulmonary
and intestinal
aspergillosis
244 39 > 6 months NA no no
18 AML sepsis Klebsiella pneumoniae
sepsis with ARDS
69 17 > 6 months 0 no CMV
reactivation
19 HLH sepsis Stenotrophomonas sepsis 72 5 > 6 months 0 no VZV, adenovirus
reactivation
20 ALL high risk sepsis septic shock,
no microorganism
identified
412 6 > 6 months NA no no
21 AML postop. external CSF drainage
for hydrocephalus, BAL
12 3 20 days 0 yes EBV, HHV6
reactivation
22 AML arrest pulmonary VOD with
pulmonary hypertension
94 23 > 6 months 0 no no
MV indicates mechanical ventilation; ICU, intensive care unit; HSCT, hematopoietic stem cell transplantation; aGVHD, acute graft-versus-host disease;
AML, acute myeloigenous leukemia; MPS, mucopolysaccharidosis; MDS, myelodysplastic syndrome; CID, combined immune deficiency; SAA, severe
aplastic anemia; ALL, acute lymphocytic leukemia; HLH, hemophagocytic lymphohistiocytosis; resp. failure, respiratory failure; neur. det., neurologic de-
terioration; postop., postoperative; VOD, veno-occlusive disease; CNS, central nervous system; ARDS, acute respiratory distress syndrome; CSF, ce-
rebrospinal fluid; BAL, bronchoalveolar lavage; NA, not applicable; CMV, cytomegalovirus; VZV, varicella zoster virus; EBV, Epstein Barr virus; HHV,
human herpes virus.
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Table 3. Clinical Characteristics of the 16 Ventilated Pediatric Hematopoietic Stem Cell Transplantation Recipients Who Died
during their ICU Admission
Primary
Diagnosis
Indication
for MV
Diagnosis
Necessitating MV
Time between
ICU and
HSCT (days)
Duration
of MV
(days)
Grade
of
aGvHD
Neutropenia
admission
to ICU
Viral infection
on admission to ICU
1 Relapsed ALL resp. failure acute GVHD, hepatic VOD 7 29 3 yes no
2 MDS resp. failure idiopathic pneumonia
syndrome
9 26 4 no no
3 Lymphoproliferative
syndrome
resp. failure pulmonary microbacterial
and nocardia infection
10 34 0 no no
4 Morbus Glanzmann resp. failure idiopathic pneumonia
syndrome, diffuse
alveolar hemorrhage
13 42 1 yes no
5 Osteopetrosis resp. failure idiopathic pneumonia
syndrome
22 33 0 no no
6 SAA resp. failure pulmonary aspergillosis 23 11 0 no no
7 Morbus Wolman resp. failure idiopathic pneumonia
syndrome, diffuse
alveolar hemorrhage
25 30 1 no CMV infection
8 Cartilage Hair
Hypoplasia
resp. failure CMV pneurmonia 40 17 2 yes CMV pneumonia,
adenovirus and EBV
reactivation
9 CVID resp. failure EBV PTLD 56 3 2 no EBV PTLD
10 relapsed ANLL resp. failure adenovirus infection 60 7 0 yes adenovirus infection
11 Wiskott-Aldrich
syndrome
resp. failure CMV, EBV infection 64 11 0 no CMV, EBV infection
12 Alpha-mannosidose resp. failure idiopathic pneumonia
syndrome
104 30 1 no adenovirus reactivation
13 Niemann-Pick
disease
resp. failure candida sepsis
with ARDS
319 6 NA no no
14 Relapsed AML neur. det. RPLS 118 3 NA yes EBV and adenovirus
reactivation
15 AML neur. det cerebral EBV infection 248 11 NA no EBV infection
16 Relapsed ALL sepsis septic shock,
no microorganism
identified
4 3 0 yes no
MV indicates mechanical ventilation; ICU, intensive care unit; HSCT, hematopoietic stem cell transplantation; aGVHD, acute graft-versus-host disease;
ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; SAA, severe aplastic anemia; CVID, common variable immunodeficiency; ANLL,
acute nonlymphocytic leukemia; AML, acute myelogenous leukemia; resp. failure, respiratory failure; neur. det., neurologic deterioration; VOD,
veno-occlusive disease; CMV, cytomegalovirus; EBV, Epstein Barr virus; PTLD, posttransplantation lymphoproliferative disease; ARDS, acute respiratory
distress syndrome; RPLS, reversible posterior leukoencephalopathy syndrome; NA, not applicable.
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nificantly associated with mortality in the multivariate
analysis.DISCUSSION
We assessed risk factors for and outcomes of me-
chanical ventilation in a recent cohort of children after
allogeneic HSCT. The main finding is that ICU mor-
tality rate was considerably lower than in previous
studies. ICU discharge was followed by a low me-
dium-term mortality rate. Our results are promising,
but they need to be confirmed in larger multicenter
studies.
There is ongoing discussion whether ICU out-
come improved over time for children after HSCT.
A recent meta-regression analysis [2] could not detect
a significant improvement over the years, but conclu-
sions were hampered by the limited availability of
current data. After the inclusion period of the meta-
regression analysis, 2 additional studies on thissubject were published. Bratton et al. [4] found a
decrease over the years in complications requiring
ICU transfer in children after HSCT. However,
once mechanical ventilation was necessary, mortality
remained unchanged in the years studied. This study
benefited from a very large sample size from a data-
base of over 3000 hospitals in the United States,
but it did not focus on ICU treatment or ICU out-
comes. It therefore included only limited information
on the reason for ICU transfer, or the acuity of illness
on admission to the ICU, which limits interpretation
of their results. Tamburro et al. [3] reviewed out-
comes of mechanical ventilation in a large cohort of
pediatric HSCT recipients between 1996 and 2004,
and found a significant improvement over the years.
Our findings are in line with their results, and even
suggest an ongoing improvement in outcomes in
more recent years, both for ICU survival (40% in
the study of Tamburro et al. versus 58% in our study)
and for 6-month survival (25% in the study of Tam-
burro et al. versus 47% in our study).
Table 4. Demographic and Clinical Data of the Children Requiring Mechanical Ventilation after Allogeneic Hematopoietic Stem
Cell Transplantation; Comparison between Survivors and Nonsurvivors
Patients Requiring MV 95% Confidence Interval for OR
Survivors
n 5 22
Nonsurvivors
n 5 16 OR Lower bound Upper bound p-Value
Gender (female) 59% 31% 0.32 0.08 1.22 .11
Median age (years) 4.3% 8.7 1.00 1.00 1.00 .29
Diagnosis
Malignancy 55% 38% 0.50 0.13 1.86 .34
Immunodeficiency 14% 25% 2.11 0.40 11.13 .43
Bone marrow failure 5% 6% 1.40 0.08 24.20 1.00
Inborn error of metabolism 18% 25% 1.50 0.31 7.19 .70
Miscellaneous inborn error 9% 6% 0.67 0.06 8.06 1.00
Type of Transplant
Bone marrow 59% 69% 1.52 0.39 5.91 .74
Cord blood 23% 31% 1.55 0.36 6.61 .71
Peripheral blood stem cells* 18% 0% .12
HLA mismatch 27% 44% 2.07 0.53 8.10 .32
Type of donor (related) 27% 25% 0.89 0.20 3.87 1.00
CMV status
Negative 59% 56% 0.89 0.24 3.28 1.00
Infection/reactivation 14% 25% 2.11 0.40 11.13 .43
Carrier 27% 19% 0.62 0.13 2.95 .71
Days o mechanical ventilation (range) 14 (2-50) 14 (3-42) 1.01 0.96 1.06 .66
Days between Tx and ICU admission (range) 70 (7-412) 32 (4-319) 1.00 0.99 1.01 .54
Oxygenation index at admission (range) 10 (2-36) 11 (2-37) 0.99 0.92 1.07 .87
HFOV 14% 44% 4.93 1.03 23.63 .05
Neutropenia at ICU admission 23% 42% 2.04 0.49 8.45 .47
GVHD >grade 2 9% 12% 3.33 0.53 21.03 .20
PRISM score at admission (range) 20 (4-40) 21 (9-36) 1.02 0.95 1.10 .64
Predicted risk of mortality-PRISM (range) 35% (2-97) 37% (5-94)
Number of organs failing on ICU day 1 (range) 2 (1-3) 2 (1-4) 1.95 0.86 4.41 .11
Number of organs failing on ICU days 2 (range) 2 (1-3) 2 (1-5) 3.10 1.06 9.05 .04
Number of organs failing on ICU days 3 (range) 2 (1-4) 3 (1-6) 2.45 0.98 6.13 .06
Indication for MV
Respiratory failure 59% 81% 3.00 0.66 13.66 .18
Neurological deterioration 18% 13% 0.64 0.10 4.03 1.00
Sepsis 14% 6% 0.42 0.04 4.48 .62
Ppostoperative* 5% 0%
Arrest* 5% 0%
MV indicates mechanical ventilation; OR, odds ratio; HLA, human leukocyte antigen; CMV, cytomegalovirus; Tx, transplantation; ICU, intensive care unit;
HFOV, high-frequency oscillatory ventilation; GVHD, graft-versus-host disease; PRISM, pediatric risk of mortality.
Data are presented as median or percentage, unless specified otherwise. Organ dysfunction was assessed following the criteria of Wilkinson et al. [12].
GVHD was graded according to Glucksberg et al. [10].
*Odds ratio and 95% confidence interval could not be calculated because no patients died in the ICU with specified risk factor.
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Pediatric Allogeneic HSCT RecipientsOur results need to be interpreted cautiously: they
are limited by the retrospective nature of the study and
by the relatively small number of patients included
from only a single center. This is especially important,
because ventilated children afterHSCT form a hetero-
geneous population, which makes it difficult to com-
pare results between studies. Moreover, we do not
know in which patients ICU admission was denied be-
cause it was considered futile. Triage decisions can in-
fluence ICU outcome, as has been shown in adult
cancer patients [14]. With these limitations in mind,
we can conclude that results are promising, but need
to be confirmed in other, preferably multicenter, stud-
ies. Because transplantation and critical care medicine
are rapidly evolving, future research on ICU treatment
in HSCT recipients would be helped with a prospec-
tively collected database by a group of dedicated
ICUs. Only then can some of the remaining questions
in this complex group of patients be answered.There may be several explanations for the im-
proved survival we found. First, it is likely that ad-
vancements in medical care contributed to better
outcomes. Second, improvements in outcome can be
explained by a lower threshold to start mechanical ven-
tilation, and by intubating less severely ill patients. In
our study, 23% of transplanted children required me-
chanical ventilation, which is comparable to the pro-
portion of patients after allogeneic HSCT in
previous European studies [6,8,15]. However, in the
study of Bratton et al. [4], only 10% of children after
allogeneic HSCT received mechanical ventilation. In
this study, 45% of nonsurvivors died without receiving
mechanical ventilation, whichmay suggest a restrictive
use of ICU care in a considerable number of children.
Patients in our study had higher PRISM scores than
patients in other studies [1,7,16,17], and their
PRISM-based risk of mortality (37%) was consider-
ably higher than in previous studies (18% [11], 19%
1392 Biol Blood Marrow Transplant 14:1385-1393, 2008J. P. J. van Gestel et al.[18], and 26% [19]). It is, therefore, unlikely that
a lower threshold to start mechanical ventilation or
a lower severity of illness explains the improved out-
come in our patients.
An interesting finding in the present study is that
the duration of mechanical ventilation (median 14
days, range: 2-50 years) was considerably longer than
reported in previous studies. This may coincide with
a higher severity of illness on admission to the ICU.
Furthermore, therapeutic options for complications
after HSCT have extended, which may lead to pro-
longed treatment in patients who would have already
died previously. The shorter duration of mechanical
ventilation in other studies may reflect withdrawal or
limitation of ICU treatment, because the need for pro-
longed mechanical ventilation has been considered
predictive for death by many physicians [11,20-23].
However, the results from the current study emphasize
that the decision to stop or limit ICU treatment should
not be based solely on the duration of mechanical
ventilation.
Organ failure was associated with ICU mortality,
but only on the second day of admission. This suggests
that lack of improvement or even progression of organ
failure despite ICU treatment gives the largest increase
in risk of mortality. The relation between organ failure
and ICU mortality is a consistent finding in nearly all
other ICU studies in HSCT recipients. It is also re-
flected in the association between HFOV and mortal-
ity, because HFOV is used in patients with the most
severe form of respiratory failure. On the other hand,
30% of patients who received HFOV in our study sur-
vived, as did the patient with the highest PRISM score,
and the patient with the highest oxygenation index.
This underscores the difficulty of identifying survivors
and nonsurvivors in a way accurate enough to guide
clinical decision making.
In conclusion, there is ongoing discussion whether
ICUoutcome improved over time for ventilated children
after HSCT. Compared to previous studies, we found
significantly better outcomes. This holds true both for
ICU survival as for survival 6 months after discharge
from the ICU. The ICU survival rate of more than
50% in the present study is promising, but needs to be
confirmed in other, preferably multicenter, studies.ACKNOWLEDGMENTS
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